Inscription Capital’s Summit Therapeutics SMMT Stock Holding History

Inscription Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,000	Closed	-$49.7K	–	554
2025 Q1	$49.7K	Buy	+12,000	New	+$241K	0.01%	339
2024 Q3	$263K	Hold	12,000	–	–	0.04%	299
2024 Q2	$93.6K	Hold	12,000	–	–	0.02%	341
2024 Q1	$49.7K	Hold	12,000	–	–	0.01%	339
2023 Q4	$31.3K	Hold	12,000	–	–	0.01%	212
2023 Q3	$22.4K	Hold	12,000	–	–	0.01%	179
2023 Q2	$30.1K	Hold	12,000	–	–	0.01%	186
2023 Q1	$21K	Sell	12,000 -5,000	-29%	-$13.6K	0.01%	203
2022 Q4	$72.3K	Hold	17,000	–	–	0.02%	197
2022 Q3	$20K	Hold	17,000	–	–	0.01%	191
2022 Q2	$17K	Hold	17,000	–	–	﹤0.01%	247
2022 Q1	$42K	Hold	17,000	–	–	0.01%	191
2021 Q4	$46K	Hold	17,000	–	–	0.01%	220
2021 Q3	$85K	Buy	+17,000	New	+$122K	0.03%	208
2021 Q2	–	Sell	-17,000	Closed	-$100K	–	382
2021 Q1	$100K	Hold	17,000	–	–	0.03%	189
2020 Q4	$80K	Hold	17,000	–	–	0.03%	179
2020 Q3	$58K	Hold	17,000	–	–	0.03%	170
2020 Q2	$50K	Hold	17,000	–	–	0.03%	139
2020 Q1	$40K	Buy	+17,000	New	+$29.2K	0.03%	128

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Inscription Capital's SMMT Position: Q2 2025 in Review

Inscription Capital sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 12,000 shares — an estimated $49.7K sold.

Inscription Capital first reported a position in SMMT in Q1 2020 and held it in 19 quarters. The position peaked at $263K in Q3 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

Inscription Capital reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
Inscription Capital sold 12,000 Summit Therapeutics shares in Q2 2025, an estimated $49.7K.
Inscription Capital first reported a position in Summit Therapeutics in Q1 2020 and held it in 19 quarters.
Inscription Capital's Summit Therapeutics position peaked at $263K in Q3 2024.
238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Inscription Capital's 13F filing for Q2 2025, filed 12 Aug 2025.